Results 161 to 170 of about 111,292 (192)

ALL-006: Assessment of Serum C-X-C Motif Chemokine Ligand 12 (CXCL12) Levels in Adult Egyptian Patients With Acute Lymphoblastic Leukemia (ALL) and Its Prognostic Value

Clinical Lymphoma Myeloma and Leukemia
Heba Hafez, M. Azzazi, V. Shawky, I. Gamal   +3 more
semanticscholar   +2 more sources

G protein activation via chemokine (C‐X‐C motif) receptor 4 and α1b‐adrenoceptor is ligand and heteromer‐dependent

FEBS Letters, 2023
It is unknown whether heteromerization between chemokine (C‐X‐C motif) receptor 4 (CXCR4), atypical chemokine receptor 3 (ACKR3) and α1b‐adrenoceptor (α1b‐AR) influences effects of the CXCR4/ACKR3 agonist chemokine (C‐X‐C motif) ligand 12 (CXCL12) and ...
Xianlong Gao, M. Majetschak
semanticscholar   +1 more source

Abstract CT534: Magnesium treatment on the demethylation of chemokine (C-X-C motif) ligand 9 (CXCL9) gene, results from the personalized prevention of colorectal cancer trial

Cancer Research, 2022
Background: Chemokine ligand 9 (CXCL9), a T-cell chemoattractant, plays a critical role in regulating antitumor immunity in cancer immunotherapy, i.e., clinical responses to anti-PD(L)-1 treatment.
Xiangzhu Zhu, Xiang Huang, Yinan Zheng, Wei Zhang, L. Shu, R. Ness, H. Murff, Chang Yu, M. Shrubsole, Lifang Hou, Q. Dai   +10 more
semanticscholar   +1 more source

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.

Journal of Clinical Oncology, 2023
TPS4200 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease for which treatments result in limited benefit. Failure of immune checkpoint blockade is attributed to multiple immunosuppressive pathways within the ...
G. Manji, M. May, I. Pellicciotta, Sarah Sta Ana, Naomi Sender, Samuel Pan, Isabelle Ross, Jianhua Hu, Q. Shi, Alexander G. Raufi   +9 more
semanticscholar   +1 more source

CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.

Journal of Clinical Oncology
4167 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease with an immunosuppressive tumor microenvironment (TME).
G. Manji, Michael S May, Edridge K. D’Souza, I. Pellicciotta, Sarah Sta Ana, Naomi Sender, Isabelle Ross, Shikun Wang, S. Bates, Linda Wu, K. Olive, Alexander G. Raufi, B. Izar   +12 more
semanticscholar   +1 more source

Abstract PR05: CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma

Cancer Research
Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease. Immune checkpoint inhibitors have thus far failed to improve outcomes due to an immunosuppressive tumor microenvironment (TME).
G. Manji, Michael S May, M. Chalabi, I. Pellicciotta, Sarah Sta Ana, Naomi Sender, Samuel S. Pan, Isabelle Ross, K. Olive, Shikun Wang, B. Izar, Ruth A. White, S. E. Bates, Alexander G. Raufi   +13 more
semanticscholar   +1 more source

CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.

Journal of Clinical Oncology
TPS4208 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) carries a 5-year relative survival of 3%. Immune checkpoint inhibitors have thus far failed to improve outcomes due to an immunosuppressive tumor microenvironment (TME).
G. Manji, Michael S May, M. Chalabi, I. Pellicciotta, Sarah Sta Ana, Naomi Sender, Samuel Pan, Isabelle Ross, Shikun Wang, B. Izar, Linda Wu, Brian W. Labadie, S. Bates, Q. Shi, Alexander G. Raufi   +14 more
semanticscholar   +1 more source

C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.

Cancer Pathogenesis and Therapy
Physiologically, the C-X-C chemokine receptor type 4 (CXCR4) signalling pathway regulates key aspects of tumor behavior (growth, metastasis, and immune evasion) and modulates immune system function.
Aswini Rajendran, Veronica Elumalai, Saranya Balasubramaniyam, Karthikeyan Elumalai   +3 more
semanticscholar   +1 more source

A pH‐Cascaded DNA Hydrogel Mediated by Reconfigurable A‐motif Duplex, i‐Motif Quadruplex, and T·A‐T Triplex Structures

Advanced Functional Materials, 2023
Yuwei Hu
exaly  

[C-X-C motif chemokine ligand 12/C-X-C motif chemokine receptor 4 regulates oxygen glucose deprivation/reoxygenation-induced autophagy in SH-SY5Y neuronal cells].

Zhonghua wei zhong bing ji jiu yi xue
Haining Meng, Chao Jia, Qingshu Li, Weifeng Xie, Sumei Wang, Yan Qu   +5 more
semanticscholar   +1 more source